Pharmacokinetic studies have long been a key element of most Phase I and Phase II clinical studies.Pharmacodynamic studies and molecular correlates are now considered important components of thesestudies. With the increasing emphasis on the development of non-cytotoxic agents directed at novel targets,'correlative' studies will be essential for the interpretation of the results and, in fact, may become theprimary endpoint of the clinical studies. Therefore, the primary aim of the Analytical Pharmacology CoreFacility (APCF) is to provide support for chemotherapy trials incorporating pharmacokinetic,pharmacodynamic and other correlative laboratory studies. An additional aim is to encourage and facilitateall cancer research, including basic and translational research, by providing a range of analytical services,such as LC/MS/MS, GC/MS, HPLC, and flameless Atomic Absorption Spectrometry (AAS). Morespecifically, the APCF provides expertise and equipment for (a) sample preparation and storage, includingtissue samples for correlative studies, (b) analysis of chemotherapeutic drugs and related compounds, and(c) analysis and interpretation of pharmacokinetic and pharmacodynamic data. In addition, the APCFpersonnel provide consultation regarding appropriate analytical methods for research projects, study design,pharmacokinetic sampling schedules, and protocol review, and they collaborate in the preparation ofmanuscripts. During the 12-month reporting period, the APCF shared resource was used by 15 CancerCenter members from 4 Research Programs and one non-aligned member. Peer-reviewed usagerepresented 89% of total usage. Annual budget for this core is $292,151, of which 64% is institutionalfunding, 15% is user fees, and 21% ($60,100) is requested from the CCSG.
| Aslamy, Arianne; Oh, Eunjin; Olson, Erika M et al. (2018) Doc2b Protects ?-Cells Against Inflammatory Damage and Enhances Function. Diabetes 67:1332-1344 |
| Zhao, Xingli; Zhang, Zhuoran; Moreira, Dayson et al. (2018) B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Mol Ther 26:695-707 |
| Weitzel, Jeffrey N; Chao, Elizabeth C; Nehoray, Bita et al. (2018) Somatic TP53 variants frequently confound germ-line testing results. Genet Med 20:809-816 |
| Ghose, Jayeeta; Viola, Domenico; Terrazas, Cesar et al. (2018) Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology 7:e1486948 |
| Castanotto, Daniela; Zhang, Xiaowei; Alluin, Jessica et al. (2018) A stress-induced response complex (SIRC) shuttles miRNAs, siRNAs, and oligonucleotides to the nucleus. Proc Natl Acad Sci U S A 115:E5756-E5765 |
| Awasthi, Sanjay; Tompkins, Joshua; Singhal, Jyotsana et al. (2018) Rlip depletion prevents spontaneous neoplasia in TP53 null mice. Proc Natl Acad Sci U S A 115:3918-3923 |
| Röth, Daniel; Chiang, Abby J; Hu, Weidong et al. (2018) Two-carbon folate cycle of commensal Lactobacillus reuteri 6475 gives rise to immunomodulatory ethionine, a source for histone ethylation. FASEB J :fj201801848R |
| Li, Yi-Jia; Du, Li; Aldana-Masangkay, Grace et al. (2018) Regulation of miR-34b/c-targeted gene expression program by SUMOylation. Nucleic Acids Res 46:7108-7123 |
| Maestrini, Davide; Abler, Daniel; Adhikarla, Vikram et al. (2018) Aging in a Relativistic Biological Space-Time. Front Cell Dev Biol 6:55 |
| Adamus, Tomasz; Kortylewski, Marcin (2018) The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn) 22:56-60 |
Showing the most recent 10 out of 1396 publications
